Histogenics Shares Move Sharply Lower On High Volume; REMINDER: Co. Expected To Meet With FDA Tomorrow To Discuss Possibly Filing BLA For NeoCart Despite It Not Meeting Its Primary Endpoint In Phase 3 Study